Shares of Merus NV (NASDAQ:MRUS) have been given a consensus rating of “Hold” by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $28.33.
Several equities research analysts have recently issued reports on MRUS shares. BidaskClub upgraded Merus from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 9th. Zacks Investment Research lowered Merus from a “buy” rating to a “hold” rating in a report on Wednesday. Berenberg Bank started coverage on Merus in a report on Wednesday. They set a “buy” rating and a $35.00 price target for the company. ValuEngine lowered Merus from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Finally, Citigroup cut their price objective on Merus from $18.00 to $16.00 and set a “neutral” rating on the stock in a research note on Thursday, March 21st.
Several hedge funds have recently modified their holdings of MRUS. Artal Group S.A. bought a new position in shares of Merus in the 4th quarter valued at approximately $2,886,000. Laurion Capital Management LP bought a new position in shares of Merus in the 3rd quarter valued at approximately $2,104,000. Aquilo Capital Management LLC raised its stake in shares of Merus by 3.6% in the 3rd quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock valued at $25,577,000 after acquiring an additional 44,799 shares in the last quarter. Morgan Stanley raised its stake in shares of Merus by 74.3% in the 3rd quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock valued at $1,415,000 after acquiring an additional 30,538 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Merus by 33.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock valued at $350,000 after acquiring an additional 4,476 shares in the last quarter. 53.06% of the stock is currently owned by institutional investors and hedge funds.
Merus (NASDAQ:MRUS) last announced its quarterly earnings results on Thursday, December 27th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter. The firm had revenue of $7.57 million for the quarter, compared to analyst estimates of $4.25 million. Merus had a negative net margin of 140.49% and a negative return on equity of 55.96%. Sell-side analysts anticipate that Merus will post -2.18 earnings per share for the current year.
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.
Featured Story: What is a conference call?
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.